Literature DB >> 25498454

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

Julie R McMullen1, Esther J H Boey1, Jenny Y Y Ooi1, John F Seymour2, Michael J Keating3, Constantine S Tam2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25498454     DOI： 10.1182/blood-2014-10-604272

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  101 in total

Review 1.  Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion.

Authors:  Deborah M Stephens; Stephen E Spurgeon
Journal:  Ther Adv Hematol       Date:  2015-10

Review 2.  Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2017-11-28

Review 3.  Targeted Therapy in Chronic Lymphocytic Leukemia (CLL).

Authors:  Erin M Pettijohn; Shuo Ma
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

Review 4.  Electrophysiologic Complications in Cancer Patients.

Authors:  Dae Hyun Lee; Sanjay Chandrashekhar; Michael G Fradley
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Oct-Dec

Review 5.  Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation.

Authors:  Federico Viganego; Robin Singh; Michael G Fradley
Journal:  Curr Cardiol Rep       Date:  2016-06       Impact factor: 2.931

6.  Ventricular arrhythmias and sudden death in patients taking ibrutinib.

Authors:  Benjamin L Lampson; Lijian Yu; Robert J Glynn; Jacqueline C Barrientos; Eric D Jacobsen; Versha Banerji; Jeffrey A Jones; Renata Walewska; Kerry J Savage; Gregory F Michaud; Javid J Moslehi; Jennifer R Brown
Journal:  Blood       Date:  2017-02-21       Impact factor: 22.113

Review 7.  Management of Older Adults with Mantle Cell Lymphoma.

Authors:  Jason T Romancik; Jonathon B Cohen
Journal:  Drugs Aging       Date:  2020-07       Impact factor: 3.923

Review 8.  Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.

Authors:  J J Shatzel; S R Olson; D L Tao; O J T McCarty; A V Danilov; T G DeLoughery
Journal:  J Thromb Haemost       Date:  2017-03-27       Impact factor: 5.824

Review 9.  Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies.

Authors:  Isaac B Rhea; Alexander R Lyon; Michael G Fradley
Journal:  Curr Oncol Rep       Date:  2019-04-04       Impact factor: 5.075

Review 10.  How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.